| The active components of ginkgo biloba can be generally devided into two kinds including flavonoid and lactone which can benefit greatly to cardiovascular system, cranial nerve system, anti-radiation, anti-inflammation as well as anti-cancer. At present, the forms of the drug is developed to liquid, pellet, pill which apply to clinical use. The sustained release form is also reported but do not have any clinical application. The creative point lies mainly in simplizing the formula. The formulation of ginkgo biloba slowed release tablet we choosed is simple and reasonable. The technic is feasible. The quality control approach is simple and stable. The main work can be summarized as follows:1．UV spectrophotometry is chosen as the analysing approach to test HPMC and EC as the frame of the sustained release tablets. Flavonoid is taken as the index to examine the cumulative release percent. Orthogonal design was utilized to obtain the best formula. The release percent of the sustained release tablets was compared to that of nomle tablets.2．HPLC is adopted to detect the cumulative release percent of three batch of samples and three batch of product. The hardness, the weight variation and the quantity contained are aslo tested to check on the formula's reliability.3．Quality research is introduced to the formula-fixed tablet including establishing UV spectrophotometry and HPLC analysing approach, the way to detect in vitro release and quality contained. 4．Stability research is carried out which is consisted of influence factor testing, accelerated and long-term testing.5．Release mechanism is studyed. The profile of the sample's in vitro release fits best to first-order kinetics, furthermore it fits well to Higuchi equation.
|
PDF Full Text Request